Cytosorbents (CTSO) Capital Expenditures Growth (3y) (2014 - 2025)
Cytosorbents (CTSO) Capital Expenditures Growth (3y) (2014 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 184.10 Bn | 176.81 Bn | 6.27 Bn | 1.64% |
| 2 | Stryker | 128.79 Bn | 125.91 Bn | 3.81 Bn | 8.49% |
| 3 | Medtronic | 108.97 Bn | 99.75 Bn | 6.41 Bn | 8.89% |
| 4 | Boston Scientific | 68.57 Bn | 67.12 Bn | 3.61 Bn | 16.83% |
| 5 | Edwards Lifesciences | 47.64 Bn | 43.97 Bn | 1.29 Bn | 1.81% |
| 6 | GE HealthCare Technologies | 28.40 Bn | 26.11 Bn | 1.98 Bn | 7.57% |
| 7 | Dexcom | 28.32 Bn | 27.20 Bn | 750.30 Mn | 0.84% |
| 8 | Smith & Nephew | 26.94 Bn | 26.36 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.33 Bn | 2.07 Bn | 2.15% |
| 10 | Cytosorbents | 23.84 Mn | 19.04 Mn | 6.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 26.40% |
| Sep 30, 2025 | -85.56% |
| Jun 30, 2025 | 27.59% |
| Mar 31, 2025 | -85.88% |
| Dec 31, 2024 | -27.17% |
| Sep 30, 2024 | 28.56% |
| Jun 30, 2024 | -71.73% |
| Mar 31, 2024 | -52.76% |
| Dec 31, 2023 | 49.20% |
| Dec 31, 2022 | -245.31% |
| Sep 30, 2022 | 254.80% |
| Jun 30, 2022 | -76.16% |
| Mar 31, 2022 | 34.41% |
| Dec 31, 2021 | 174.29% |
| Sep 30, 2021 | -261.10% |
| Jun 30, 2021 | 51.78% |
| Mar 31, 2021 | 20.83% |
| Dec 31, 2020 | -26.66% |
| Sep 30, 2020 | -13.10% |
| Jun 30, 2020 | -20.09% |